news

MSD Animal Health receives marketing authorization from European Commission for BRAVECTO™

Posted: 17 February 2014 | | No comments yet

MSD Animal Health announced that following a positive opinion from the Committee for Medicinal Products for Veterinary Use, the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO™…

Merck logo

MSD Animal Health, known as Merck Animal Health in the United States and Canada, announced today that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). This is the first and only treatment that has been shown to quickly and effectively kill fleas and ticks for up to 12 weeks in a single dose.*

“BRAVECTO provides a powerful new weapon in the fight against these dangerous parasites,” said KJ Varma, senior vice president, Research & Development, MSD Animal Health. “We are incredibly proud to bring this new innovative chewable tablet to dog owners, which we could not have done without the partnership of the clinical veterinarians who worked with us to bring this advancement to market.”

BRAVECTO is indicated for the treatment of tick and flea infestation on dogs. It is a systemic insecticide and acaricide that provides*:

  • Immediate and persistent flea-killing activity for 12 weeks (Ctenocephalides felis);
  • Immediate and persistent tick-killing activity for 12 weeks (Ixodes ricinus, Dermacentor reticulatus and Dermacentor variabilis); and
  • Immediate and persistent tick-killing activity for 8 weeks (Rhipicephalus sanguineus).

“We are delighted with the CVMP’s decision to grant marketing authorization for BRAVECTO,” said David Hallas, associate vice president, MSD Animal Health. “Now veterinarians and pet owners have a highly effective treatment option that works quickly and lasts longer than the currently available once-monthly treatment options.”

The active substance of BRAVECTO, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatits (FAD). The most common side effects are mild and transient gastrointestinal effects.

BRAVECTO will be launched in Germany, Spain, Italy, France, The Netherlands and the United Kingdom in April 2014. It will be introduced in additional European countries in the coming months.

Related organisations